Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19118056 | 0.90 | PDE4B (0.60) | PDE4BGRIN2B | |
| SCHEMBL17784217 | 0.90 | PDE4B (0.60) | PDE4BGRIN1GRIN2BPTGIRPTGDR | |
| SCHEMBL17784235 | 0.85 | PDE4B (0.56) | PDE4B | |
| SCHEMBL17784207 | 0.84 | PDE4B (0.55) | PDE4B | |
| SCHEMBL16447934 | 0.83 | PDE4B (0.54) | PDE4B | |
| SCHEMBL17784218 | 0.83 | PDE4B (0.69) | PDE4BGRIN1GRIN2BPTGIRWDR5 | |
| SCHEMBL17784208 | 0.83 | PDE4B (0.54) | PDE4B | |
| SCHEMBL17784228 | 0.82 | PDE4B (0.79) | PDE4BPIK3CD | |
| SCHEMBL17784202 | 0.82 | PDE4B (0.53) | PDE4B | |
| SCHEMBL16448257 | 0.82 | PDE4B (0.53) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3030565-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015018534-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | PDE4B 2/4885GRIN1 4089/4885GRIN2B 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.